Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
aHSCT versus alemtuzumab or ocrelizumab in highly active relapsing-remitting multiple sclerosis
2019-001549-42Phase 3Unknown
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
- Start
- Feb 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of alemtuzumab and ocrelizumab in multiple sclerosis (MS) (2 arms), sponsored by Sheffield Teaching Hospitals NHS Foundation Trust. Primary endpoint: Maintenance of NEDA status over 2 years. Status: unknown.
02
Drugs
alemtuzumabocrelizumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2019-001549-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001549-42.